Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  British American Tobacco Plc    BATS   GB0002875804

BRITISH AMERICAN TOBACCO PLC

(BATS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

British American Tobacco : BAT announces appointment of Dr Hutan Ashrafian as Chief Medical Officer

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:55am EDT
  • Appointment supports BAT's commitment to underpinning New Category products with world class science and reducing the health impact of its combustibles business.

BAT has appointed Dr Hutan Ashrafian as Chief Medical Officer, effective 14 September 2020.

In this role, Dr Ashrafian will be responsible for overall medical governance and ensuring robust medical processes and oversight are applied to all aspects of BAT's clinical studies and post-market surveillance.

BAT is committed to reducing the health impact of its business through offering a range of enjoyable and less risky products. Dr Ashrafian will play a key role in the ongoing development and expansion of BAT's multi-category approach, which offers consumers a wide range of potentially lower risk alternatives to cigarettes including e-cigarettes, tobacco heated products and modern oral nicotine pouches.

Specifically, he will provide medical oversight to both BAT's Human Research Committee and Product Stewardship Council. Dr Ashrafian will also play an important role in helping to define and generate evidence that supports and substantiates the tobacco harm reduction potential of BAT's new categories from a disease perspective.

Dr David O'Reilly, Director, Scientific Research, commented: 'We are delighted to have Hutan join BAT and become a member of the R&D leadership team. The Chief Medical Officer has always been a critical role at BAT as we strive to ensure all of the studies we undertake are of the highest standards from a quality and integrity perspective. His appointment will provide even greater confidence in our products for the science community and ultimately, consumers. It also demonstrates our ongoing commitment to delivering A Better Tomorrow by ensuring the quality and efficacy of our New Category products.'

Dr Ashrafian is a senior clinician-scientist and surgeon. His career has seen him lead large research and clinical teams, working at population and precision medicine levels, to achieve the highest quality real world evidence and translational healthcare. He has extensive experience in strategy and driving national and international health policy with cabinet-level politicians, civil servants, and heads of state.

He qualified in medicine at University College London where he was also awarded an honours degree in Immunology and Cell Pathology. His training in surgery also led to the award of the Arris & Gale lectureship at the Royal College of Surgeons of England. He a holds a PhD in Computational Physiology and Metabolic Surgery from Imperial College London and a health economics-focused MBA with Distinction from Warwick Business School.

Prior to his appointment at BAT, Dr Ashrafian was simultaneously Chief Scientific Adviser at the Institute of Global Health Innovation, Imperial College London; an Honorary Senior Clinical Fellow in Surgery at Imperial College Healthcare NHS Trust; Academic Lead for the Big Data Analytical Unit, Imperial College London; Deputy Director (Academic Lead) for the NHS Digital Academy; Co-Founder and Chief Medical Officer at Oxford Medical Products Ltd.

Dr Ashrafian's experience includes the application of biomedical and technological platforms to address a broad range of healthcare issues. These include the molecular biology of non-communicable diseases and cancer, digital health, behavioural interventions in new pathways of care and remote sensing technologies in the community and health centres, robotics and devices in surgery, computational modelling, artificial intelligence (AI) and machine learning, big data analytics, population screening and diagnostics and bioinformatics. He has co-designed novel digital health tools and apps and has invented novel surgical approaches. His wide-ranging work has been published in a variety of leading journals including Nature, The Lancet and The New England Journal of Medicine.

Enquiries

Press Office
+44 (0) 20 7845 2888 (24 hours) | @BATPress

Disclaimer

British American Tobacco plc published this content on 18 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 10:54:09 UTC


share with twitter share with LinkedIn share with facebook
All news about BRITISH AMERICAN TOBACCO PLC
10/15BRITISH AMERICAN TOBACCO : Names Luc Jobin as Next Chairman
DJ
10/13LEXARIA BIOSCIENCE : Advances Antiviral Research Initiative Using DehydraTECH(TM..
AQ
10/07Kenya's health minister questions licensing of BAT's LYFT nicotine pouches
RE
10/07BRITISH AMERICAN TOBACCO : 2020 Annual General Meeting – Voting Results Up..
PU
10/06BRITISH AMERICAN TOBACCO : Tender Offer Pricing -3-
DJ
10/06British American Tobacco PLC Tender Offer Pricing -2-
DJ
10/06British American Tobacco PLC Tender Offer Pricing
DJ
10/06Companies Give Up Cash Cushions to Buy Back Debt
DJ
10/06BAT : JP Morgan gives a Buy rating
MD
10/01BRITISH AMERICAN TOBACCO PLC : Ex-dividend day for quarterly dividend
FA
More news
Financials
Sales 2020 25 641 M 33 468 M 33 468 M
Net income 2020 7 065 M 9 221 M 9 221 M
Net Debt 2020 40 873 M 53 348 M 53 348 M
P/E ratio 2020 8,05x
Yield 2020 8,59%
Capitalization 58 854 M 76 940 M 76 817 M
EV / Sales 2020 3,89x
EV / Sales 2021 3,66x
Nbr of Employees 56 689
Free-Float 93,1%
Chart BRITISH AMERICAN TOBACCO PLC
Duration : Period :
British American Tobacco Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRITISH AMERICAN TOBACCO PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 3 632,78 GBX
Last Close Price 25,14 GBX
Spread / Highest target 18 201%
Spread / Average Target 14 353%
Spread / Lowest Target 8 777%
EPS Revisions
Managers
NameTitle
Jack Marie Henry David Bowles Chief Executive Officer & Executive Director
Richard George William Burrows Chairman
Alan Davy Operations Director
Tadeu Luiz Marroco Executive Director & Finance Director
David O'Reilly Director-Research & Science
Sector and Competitors
1st jan.Capitalization (M$)
BRITISH AMERICAN TOBACCO PLC-20.33%76 608
PHILIP MORRIS INTERNATIONAL INC.-13.44%114 694
ALTRIA GROUP, INC.-22.72%71 678
JAPAN TOBACCO INC.-17.82%33 829
ITC LIMITED-29.09%28 054
IMPERIAL BRANDS PLC-30.44%15 903